% | $
Quotes you view appear here for quick access.

Venaxis, Inc. Message Board

jrdelane 334 posts  |  Last Activity: 2 hours 52 minutes ago Member since: Dec 5, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • jrdelane jrdelane Apr 21, 2015 12:43 AM Flag

    Well, did you? Somebody please light the fire!

  • jrdelane jrdelane Apr 20, 2015 8:32 PM Flag

    Mo, here we are again, this time I have a decent position. Been trading it, this time looks more like a hold. Averaged down recently, now under 2.50. Easy double but likely triple.

  • jrdelane jrdelane Apr 20, 2015 12:50 PM Flag

    holding since 2.52, but added at 2.36 Friday, average now 2.48!

  • Reply to


    by nysigi Apr 19, 2015 9:15 PM
    jrdelane jrdelane Apr 20, 2015 12:52 AM Flag

    Before trial news, partnership news, or new analyst reports, our stock price has little stability and it will just trade without trending, expect it, just don't make ant short term plans for your invested funds here. You just don't want to be out of the name when they start releasing their data.

  • Reply to

    $2 a share coming VERY soon!

    by lovepipes Apr 18, 2015 3:11 PM
    jrdelane jrdelane Apr 18, 2015 8:16 PM Flag

    That's it, for our enjoyment and personal gratification. I like the values you mention, and will keep reading your posts, I like your positivity. Partnership? Bring it on!

  • Reply to

    $2 a share coming VERY soon!

    by lovepipes Apr 18, 2015 3:11 PM
    jrdelane jrdelane Apr 18, 2015 8:01 PM Flag

    One thing about soon is you can't be as wrong by saying it, since it's not on anyone's calendar system. I don't think "by the end of the year" is in anyone's mind as "soon" so why even post it? Hey, I'm long here like you are, but what good does this do? Wishing won't make it happen, there isn't a fact associated with your opinion, it's just an opinion. Do you think Baker Bros would (even privately) say such a thing? If you're just having fun, okay, but raising everyone's expectations without justification may lead to disappointment, and shares held for short term loss. We don't want that kind of trader here. At the quarterly conference call, maybe there will be mention of something by management that could send shares higher. That's my hope, but I can't predict so I'm not going to say it.

  • Reply to

    On Stryker's Home Page

    by market_mania Apr 18, 2015 6:21 PM
    jrdelane jrdelane Apr 18, 2015 7:04 PM Flag

    This hasn't been reported here on YMB so thanks for being on it. The event took place in March, so the factoid didn't create any interest in the market. We are drifting lower--the chart seems to indicate we've got more weakness ahead. Here's an expanded view of that announcement: ALLENDALE, N.J., March 24, 2015 /PRNewswire/ -- Stryker Corporation's Spine and Trauma & Extremities Divisions will be launching BIO4™, the next generation viable bone matrix at booth #443 during the American Academy of Orthopaedic Surgeons Annual Meeting in Las Vegas, NV from March 24-28th.

    From the creators of the original allograft cellular bone matrix, Osiris Therapeutics, Inc., comes the next generation, BIO4, a viable bone matrix containing endogenous bone forming cells including mesenchymal stem cells, osteoprogenitor cells, osteoblasts, osteoinductive and angiogenic growth factors. BIO4 possesses all four characteristics involved in bone repair and regeneration: osteoconductive, osteoinductive, osteogenic and angiogenic.1, 2 It is a safe alternative to bone autograft that minimizes the potential for harvest site co-morbidities3.

    "With the introduction of BIO4, Stryker now plays in the growing $199M4 Cellular Allograft Market," said Spencer Stiles, President, Stryker Spine. "Stryker offers one of the most comprehensive biologics portfolios on the market featuring the #1 selling synthetic bone graft5, Vitoss, and the next generation viable bone matrix, BIO4."

  • jrdelane jrdelane Apr 18, 2015 1:11 AM Flag

    After this week's carnage in IDRA, my position here is now threatening red within a dime. I had an enormous trading profit that I let escape, wasn't expecting this much of a collapse! Pullback doesn't describe what happened here. Good luck friends, shorties take yours and let it recover!

  • jrdelane jrdelane Apr 17, 2015 2:55 PM Flag

    Today's price action of the continued downtrend is but blip on the screen in the big picture, yet it is real money. Got to manage your emotions and keep your eye on the prize, especially hard on you if you had big gains and watched them disappear (we beat ourselves up over this missed opportunity using hindsight). I think this bleed will stop at $3.27 worst case, which is the 250-dma. On March 27th, intra-day lows reached $3.25, or the 250-dma, and it bounced right back up into the $3.80's. These development stage companies are difficult to hold for long term gains if you watch them too closely.

    Sentiment: Hold

  • Reply to

    OFF TOPIC - NVIV --- up 457.59% today!

    by jacknjill777 Apr 17, 2015 1:31 PM
    jrdelane jrdelane Apr 17, 2015 1:40 PM Flag

    Jackie, your headline is misleading, the stock is actually down today over 3%now, after an early pop this morning. No doubt, point well taken, what a nice call!

  • Reply to

    Sold My NWBO for more BTX

    by colinelbasani Apr 16, 2015 2:04 PM
    jrdelane jrdelane Apr 17, 2015 2:55 AM Flag

    Mistake to have sold NWBO THIS MORNING!

  • Reply to

    this is idera

    by oilup12345 Apr 16, 2015 1:27 PM
    jrdelane jrdelane Apr 16, 2015 1:37 PM Flag

    We have to keep reminding ourselves why we invested, since the stock is flagging amidst an otherwise bullish backdrop in biotech. Thanks Lube.

  • Reply to

    Happy Sickle Cell Advocacy Day!!

    by lovepipes Apr 16, 2015 9:25 AM
    jrdelane jrdelane Apr 16, 2015 11:33 AM Flag

    Bluebird Bio sure inspires huge forward value for our MSTX shares, given what the market hopes will develop there, and their candidate potentially is a game changer but years out, maybe in 2020 they succeed in bringing LentiGlobin to market. Their market cap is over $4B now, trading around $134 a share.

  • jrdelane jrdelane Apr 16, 2015 1:48 AM Flag

    I own 60k shares here so it's part of my 2015 investment thesis. I am glad however it's just a piece of my entire portfolio though, because it isn't producing a return as yet. I am down 9 per cent, but by q1 that will have faded in the run we will have had by then. I like our chances, just don't like the stock action. It keeps getting slammed down.

  • Reply to

    Inverted Head and Shoulders forming

    by jrdelane Apr 2, 2015 12:01 PM
    jrdelane jrdelane Apr 15, 2015 2:11 AM Flag

    Anyone watching this right shoulder? I tell you, we're trending up, there's got to be some news about to break driving this much, much higher! 6-bagger in 3 years to $20 per share.

  • Reply to

    TA compelling here.............

    by tasermac Apr 10, 2015 2:37 PM
    jrdelane jrdelane Apr 15, 2015 12:11 AM Flag

    It's been over 100 days of sideways trading, so the supporting base for the launch is surely built and now reinforced. We know there's a lot of action behind the curtain, will be great to see the new cast of characters make their contributions to EPS and pps.

  • jrdelane jrdelane Apr 14, 2015 10:08 AM Flag

    Agree. Mush brain, nonsensical posts, irrelevant to what happens here, or what people are interested in reading.

  • Reply to

    SA Article-SYN to increase 50-100%....

    by tina_bridgett50 Apr 14, 2015 9:07 AM
    jrdelane jrdelane Apr 14, 2015 10:04 AM Flag

    Synthetic Biologics

    SYN is an emerging biopharmaceutical company listed on the NYSE. It is developing Trimesta for Multiple Sclerosis (MS), which is currently entering Phase 3, as well as multiple other drugs indicated for the anti-infective space. These include drugs targeting C. diff, Irritable Bowel Syndrome (IBS), and Pertussis - all of which are largely untapped markets worth billions to any company that successfully penetrates them. Without getting into the science of each drug, it is important to note that we believe the pipeline is validated, to some extent, by major interest in SYN from Intrexon Corporation (NYSE:XON) and Randall J. Kirk, Founder and CEO of XON and a widely known billionaire biotech guru. In fact, XON is partnered with SYN to advance SYN-004, which is currently under Phase 2a study with results expected later this year.

    While we have previously offered support for a long-term buy thesis on SYN, accessible here, we have never offered support for a short-term buy thesis. Accordingly, it seems that the market has neglected to comprehensively grasp the value potential of the upcoming partnership announcement expected in Q2 2015. At this time, SYN is expected to announce it has partnered its Trimesta program, as CEO Jeff Riley has repeatedly stated in recent months that several partnership discussions are already underway - with the stated goal of closing a deal in Q2. We believe any partnership for Trimesta is likely to offer very large incentives to SYN in the form of upfront fees and milestone and royalty payments. In conjunction, we see a move to the mid $3s to low $4s. So, even if you don't understand its pipeline (which is highly diversified and deeply rooted in multiple high-value indications), simply invest in SYN for the hype that is expected to drive shares higher as we approach Q2. In the meantime, we see shares rising to at least the $3 range before a partnership is announced. Consensus estimates for SYN as formulated by TipRanks support 65% upside in 12 months. This supports our buy thesis and corroborates our price target range.

  • Reply to

    HART is under accumulation by Funds

    by savevox Apr 10, 2015 12:40 PM
    jrdelane jrdelane Apr 13, 2015 12:46 AM Flag

    And visionary retail holders. Quietly accumulating, yep!

  • jrdelane jrdelane Apr 10, 2015 1:07 AM Flag

    Remember, 3 in 3. It takes patience and time for a crop of young drugs to mature in a pipeline. $3 in 2018! Got that idea here from one of our faithful longs. Good luck working on that!

0.58+0.05(+9.45%)2:53 PMEDT